Sakalys Dovydas, Dvylys Dominykas, Simuntis Regimantas, Leketas Marijus
Lithuanian University of Health Sciences, Faculty of Odontology.
Lithuanian University of Health Sciences, Department of Maxillofacial Surgery, Kaunas, Lithuania.
J Craniofac Surg. 2020 May/Jun;31(3):637-641. doi: 10.1097/SCS.0000000000006098.
Nowadays, temporomandibular joint (TMJ) arthroscopies are often finished with intraarticular injections. There are a couple of different substances that can be injected into the articular cavity following arthroscopy; however, it is still unclear which one can help to reach the best clinical results.The aim of this systematic review was to compare different substances that can be injected intraarticularly following TMJ arthroscopy to enhance clinical success.A review protocol was registered in PROSPERO (Registration number: CRD42018114833). An electronic search was performed using PubMed, Cochrane Library, PlosOne, and Science Direct databases using a combination of the terms "temporomandibular" and "arthroscopy" to identify clinical trials published from 2009 until 2019. Mean differences of pain levels were evaluated in random-effect meta-analysis.In total, 951 records were screened, of which only 3 fulfilled the inclusion criteria and were included into qualitative data synthesis, and only 2 articles were included into quantitative data analysis.The results showed that subjects who received plasma rich in growth factors intraarticular injections had statistically significantly lower pain levels 18 months postoperatively than patients who received hyaluronic acid injections.The results of the meta-analysis revealed that intraarticular injections followed by TMJ arthroscopy were more effective than arthroscopy alone in pain management (mean difference = -1.00, 95% confidence interval: -4.76 to 2.77, I = 97% with significant heterogeneity).The authors conclude that, although the sample is not extensive (only 3 studies), a tendency towards the superiority of plasma rich in growth factors over other treatments is seen in pain management of TMD.
如今,颞下颌关节(TMJ)关节镜检查通常会在关节内注射的情况下完成。关节镜检查后有几种不同的物质可注射到关节腔中;然而,目前仍不清楚哪种物质能帮助获得最佳临床效果。本系统评价的目的是比较颞下颌关节镜检查后可关节内注射的不同物质,以提高临床成功率。一项评价方案已在国际前瞻性系统评价注册库(PROSPERO)注册(注册号:CRD42018114833)。使用PubMed、Cochrane图书馆、PlosOne和科学Direct数据库进行电子检索,通过组合“颞下颌”和“关节镜检查”等术语来识别2009年至2019年发表的临床试验。在随机效应荟萃分析中评估疼痛水平的平均差异。
总共筛选了951条记录,其中只有3条符合纳入标准并被纳入定性数据综合分析,只有2篇文章被纳入定量数据分析。结果表明,接受富含生长因子血浆关节内注射的受试者在术后18个月时的疼痛水平在统计学上显著低于接受透明质酸注射的患者。荟萃分析结果显示,颞下颌关节镜检查后进行关节内注射在疼痛管理方面比单纯关节镜检查更有效(平均差异=-1.00,95%置信区间:-4.76至2.77,I=97%,具有显著异质性)。作者得出结论,尽管样本量不大(仅3项研究),但在颞下颌关节紊乱病的疼痛管理中,富含生长因子的血浆相对于其他治疗方法有优越性的趋势。